Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.

A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.

Ocular toxicities could be the reason.

Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.

Adverse events will be closely watched when full data are reported.

Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.

Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.